A. Menarini GmbH is the German subsidiary of the Menarini Group, an Italian multinational pharmaceutical and diagnostics company. Operating primarily from Berlin, A. Menarini GmbH focuses on the marketing, sales, and distribution of a wide range of pharmaceutical products in Germany across various therapeutic areas. These often include cardiology, oncology, pain/inflammation, asthma/COPD, and diabetes. The company is committed to providing innovative healthcare solutions and high-quality medicines to patients and healthcare professionals in the German market, leveraging the research and development capabilities of the broader Menarini Group.
Serves as the primary hub for Menarini's commercial operations in Germany, including sales, marketing, medical affairs, regulatory activities, and distribution management for the German market.
Modern office complex designed to facilitate collaboration and efficient operations. As part of the larger Berlin-Chemie campus, it benefits from proximity to research, production, and logistics facilities, though A. Menarini GmbH itself is primarily focused on commercial activities.
The work culture likely combines German efficiency and structured processes with the patient-centric and innovative focus of the Menarini Group. Emphasis is placed on professionalism, teamwork, and contributing to healthcare advancements.
The Berlin headquarters is strategically important for accessing and serving the German pharmaceutical market, one of the largest and most influential in Europe. It enables direct engagement with German healthcare stakeholders.
A. Menarini GmbH is a key component of the Menarini Group's extensive international network. The Menarini Group operates in over 140 countries worldwide through its own subsidiaries, including A. Menarini GmbH in Germany, and partnerships. Globally, the Group supports functions like pharmaceutical research and development, drug manufacturing, quality assurance, marketing, sales, and distribution across diverse therapeutic areas such as cardiovascular diseases, oncology, pain management, respiratory illnesses, and metabolic disorders.
Glienicker Weg 125
Berlin
Berlin
Germany
Address: Märkische Allee 69, 14979 Großbeeren (Berlin-Chemie AG Logistics Center)
Ensures efficient warehousing, packaging, and distribution of pharmaceutical products, supporting the commercial activities managed from the Berlin headquarters.
Address: Via dei Sette Santi 3, 50131 Florence, Italy
Central hub for global governance, R&D pipeline management, and corporate functions supporting all subsidiaries, including A. Menarini GmbH.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, A. Menarini GmbH' leadership includes:
A. Menarini GmbH has been backed by several prominent investors over the years, including:
Specific executive changes for A. Menarini GmbH are not always widely publicized. However, leadership roles within the broader Berlin-Chemie AG or Menarini Group impacting German operations may be announced. No major, widely publicized C-suite changes specifically for 'A. Menarini GmbH' were identified in the immediate past 12 months. Changes are typically announced via official company channels.
Discover the tools A. Menarini GmbH uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
A. Menarini GmbH, as part of the Menarini Group and its German entity Berlin-Chemie, likely utilizes email formats common within the group. These typically involve combinations of the employee's first and last name with the company domain.
Common formats include [first_initial][lastname]@berlin-chemie.de (e.g., jdoe@berlin-chemie.de) or [firstname].[lastname]@berlin-chemie.de (e.g., jane.doe@berlin-chemie.de). The global @menarini.com domain might also be used by some executives or for international correspondence.
Format
m.mustermann@berlin-chemie.de
Example
80%
Success rate
Menarini Group Website • February 13, 2024
The Menarini Group announced positive top-line results from the Phase 3 EMERALD clinical trial evaluating elacestrant in ER+, HER2- metastatic breast cancer patients in Japan, South Korea, and Taiwan. This demonstrates ongoing commitment to oncology R&D globally....more
berlin-chemie.de • November 20, 2023
Berlin-Chemie, part of the Menarini Group, shared positive results and insights from its participation in the Diabetes Autumn Conference 2023, highlighting its commitment to diabetes care and new therapeutic approaches in Germany....more
Menarini Group Website • October 26, 2023
The Menarini Group entered into an exclusive global licensing agreement with Insilico Medicine for the development and commercialization of a novel small molecule inhibitor of KAT6A for treating ER+/HER2- breast cancer. Menarini will lead clinical development and commercialization, impacting its oncology portfolio available through subsidiaries like A. Menarini GmbH....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including A. Menarini GmbH, are just a search away.